Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07151105 · ClinicalTrials.gov registry record · NA
Anti-inflammatory Activities of Vitamin C Supplementation on the Gut Barrier Function in Adults With Obesity
A NA study of Adequate Vitamin C Status and Inadequate Vitamin C Status, sponsored by Ohio State University.
- Recruiting
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT07151105: Recruiting NA study of Adequate Vitamin C Status and Inadequate Vitamin C Status, sponsored by Ohio State University.
NCT07151105 is a NA study of Adequate Vitamin C Status and Inadequate Vitamin C Status that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07151105, a NA study of Adequate Vitamin C Status and Inadequate Vitamin C Status, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is testing whether taking vitamin C every day can help improve gut health and reduce inflammation in adults with obesity. Poor gut health-sometimes called "leaky gut"-can allow harmful substances from bacteria to enter the bloodstream, which may lead to inflammation and increase the risk of heart disease and liver problems. Participants will complete two study periods, each lasting two weeks, with a two-week break in between. In one period, they will take vitamin C; in the other, a placebo. During each period, researchers will collect blood, urine, and stool samples, ask participants to track their diet and activity, and perform a test to measure gut permeability. There are minimal risks, such as discomfort from blood draws or temporary stomach upset from a sugar drink. While participants may not directly benefit, their involvement will help researchers learn whether vitamin C is a safe and effective way to improve gut health in people with obesity.
Primary Outcome
Urinary excretion ratio of lactulose/mannitol following oral ingestion of these sugar probes.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Vitamin C Supplement + Low Vitamin C Diet
- DIETARY_SUPPLEMENT Placebo + Low Vitamin C Diet
Study Locations (1)
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-12-30 |
| Phase | NA |
What NCT07151105 shows while recruiting
NCT07151105 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Adequate Vitamin C Status appearing as the primary indexed condition, and to 2 interventions - of which Vitamin C Supplement + Low Vitamin C Diet is the first listed.
NCT07151105 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07151105 about?
NCT07151105 is a clinical study titled "Anti-inflammatory Activities of Vitamin C Supplementation on the Gut Barrier Function in Adults With Obesity". This study is testing whether taking vitamin C every day can help improve gut health and reduce inflammation in adults with obesity. Poor gut health-sometimes called "leaky gut"-can allow harmful substances from bacteria to enter the bloodstream, which may lead to inflammation and increase the risk ...
What is the current status of trial NCT07151105?
This trial is currently recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2025-10-01. Estimated completion is 2026-12-30.
What conditions does trial NCT07151105 study?
This clinical trial studies the following conditions: Adequate Vitamin C Status, Inadequate Vitamin C Status.
What interventions are being tested in trial NCT07151105?
The interventions under investigation include: Vitamin C Supplement + Low Vitamin C Diet (DIETARY_SUPPLEMENT), Placebo + Low Vitamin C Diet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07151105?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07151105 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07151105's enrollment target sits among peer trials
34 1570th of 2000 higher than 427 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI